Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report May – Jul 2022: Steady sales growth fuelled by increased market penetration in the US

The period May 1[st] 2022 – JUl 31[st] 2022 · Net sales amounted TSEK 17 235 (12 882), which is an increase of 34% compared with the corresponding period last year. Strong growth of 45% in the US market, compared with the corresponding period last year. · Operating profit amounted to TSEK 366 (1 247) · Net profit amounted to TSEK -550 (1 282) · Cashflow from operating activities amounted to TSEK -13 030 (-8 553),-4.8 MDR project and -12.8 Accounts Receivables, respectively. · Earnings per share amounted to -0.03 SEK (0.08) Significant events in the period · The

The board of Bioservo resolves on a guaranteed preferential issue of units of approximately SEK 30.3 million conditional on the approval of an extraordinary general meeting

The board of Bioservo Technologies Aktiebolag (publ) ("Bioservo" or the "Company") has today resolved on an issue of units, consisting of shares and warrants with preferential rights for existing shareholders (the "Rights Issue"). In the case of full subscription in the Rights Issue, Bioservo will initially receive approximately SEK 30.3 million before issuing costs, and if all warrants are fully exercised, Bioservo can receive an additional approximately SEK 30.3 million before issuing costs. The Rights Issue requires the approval at an extraordinary general meeting on September 19, 2022.

Interim report January – June 2022

The period in summary First half year January 1 – June 30, 2022 –      On March 23 the first batch of Strangvac was released for sale in Sweden, and in the end of May we passed another milestone in the fight against strangles when Strangvac was released for sale in Denmark. –      On April 25 we announced positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with Streptococcus suis. –      Progress in development of vaccine to prevent mastitis in dairy cows caused by Staphylococcus aureus. –      During

DanCann Pharma A/S intends to resolve on a partially (77 percent) guaranteed rights issue of approximately DKK 28.5 million

COPENHAGEN, Denmark, August 31, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Board of Directors in DanCann Pharma today announces its intention to resolve on a partially (77 percent) guaranteed rights issue of units corresponding to a total of approximately DKK 28.5 million (the “Rights Issue”). An Extraordinary General Meeting (“EGM”) is proposed to authorize the Board of Directors to resolve on the Rights Issue. The EGM is planned to be held on 20 September 2022 and the notice will be published

Orthex Corporation: Managers’ Transactions – Markus Hellström

Orthex Corporation, Managers’ transactions, 31 August 2022 at 9.30 a.m. EEST_______________________________________Person subject to the notification requirementName: Markus HellströmPosition: Member of the BoardIssuer: Orthex CorporationLEI: 7437008RMK8BSWN39T09Notification type: INITIAL NOTIFICATION_______________________________________Transaction date: 2022-08-30Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000480504Nature of the transaction: ACQUISITIONTransaction details(1): Volume: 1,500 Unit price: 5.14 EURAggregated transactions(1)

Stayble Therapeutics reaches important milestone - phase IIb-study fully recruited

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363 for chronic disc-related low back pain. Recruitment is thereby completed. The patients will be followed for 12 months after inclusion. Final results from the study are expected to be available in Q4 2023 after the Company has compiled and analyzed data from all treated patients in the study.The primary objective of the study is to investigate the effect of STA363 on ongoing pain (primary endpoint) in patients suffering from chronic

BioStock: Saniona receives heightened interest in Q2

During 2022, Danish biotech Saniona has initiated restructuring measures that are expected to reduce future operating expenses by up to 75 per cent. Meanwhile, the company has seen a sharp increase in interest from over 50 companies that now have carried out evaluations on one or more of Saniona’s preclinical or clinical pipeline programmes.Read the article about Saniona at biostock.se: https://www.biostock.se/en/2022/08/saniona-receives-heightened-interest-in-q2/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Sectra extends medical diagnostics business to include genomics IT

Linköping, Sweden – August 31, 2022 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) is initiating a new business unit to drive innovation and product development within the area of genomics. In the future, Sectra’s enterprise diagnostic IT platform will be extended to efficiently handle genomics information—a further step in Sectra’s drive towards integrated diagnostics. This multidisciplinary approach is particularly important in cancer care.“Genetic information is becoming increasingly important in diagnostics and precision medicine,

Correction: Dentalum Operations AB (publ) half year report, January -June 2022

In the interim report published yesterday, errors were found regarding the company's cash flow statements and pro forma net leverage ratio. The The Group's cash flow for the second quarter amounts to SEK -46,709 thousand and the parent company's cash flow for the same period amounts to SEK -34,565 thousand. The pro forma net leverage ratio for the period LTM 06/22 amounts to 2.7. The corrected report is attached in its entirety.Maintained profitability and continued growth Second quarter, April - June 2022 · Operating revenue increased by 72.8 % to SEK 85.8 million (49.7). ·

Biosergen receives a loan of SEK 7 million to finance continued development

August 31, 2022: Biosergen AB (“Biosergen” or the “Company”) announces that it has entered into a loan agreement of SEK 7 million (the “Loan”). The Loan will be used to continue the development of BSG005 in accordance with existing plans until the end of 2022. Longer term funding solutions will be evaluated and decided at a later moment.The Loan is issued by Biosergens largest shareholder Östersjöstiftelsen (the “Lender”). The main  terms of the Loan are as follows: · The Lender agrees to lend to the Company a maximum total principal amount of SEK  7,000,000 (seven million Swedish

Thailand kicks off for winter with Amazing Thailand New Chapters Roadshow in Denmark and Stockholm

Amazing Thailand New Chapters Roadshow to Nordic & Baltic 2022 is Tourism Authority of Thailand very first roadshow in the Nordic region after the pandemic. Over 40 participants from travel agencies, charters and airlines from the Nordic and Baltic market joined the Amazing Thailand Roadshow to meet 18 representatives from hotels and destination management companies from Thailand. The events took place in Denmark on August 23 and in Stockholm on August 24. (Participants from travel agencies, charters and airlines from the Nordic and Baltic market and 18

Ratos AB – change in number of shares and votes

The third opportunity to exercise warrants according to the incentive program for the CEO and other key personnel in Ratos decided on by the 2018 Annual General Meeting and the first opportunity to convert convertible debentures into shares according to the incentive program for the CEO and other key personnel in Ratos decided on by the 2019 Annual General Meeting was completed in August 2022. Through the exercise of 40,000 warrants and conversion of 738,800 convertible debentures, the number of Class B shares increased by 778,800 and the number of votes by 77,880. After the increase, the

Loudspring´s Half-year review 1 January – 30 June 2022

Loudspring Oyj Company release 31 August 2022 at 9:00 (EET) H1 ended with a growing order book despite challenging operating environment The full half-year review 2022 report in PDF can be found here.  This release is a summary of Loudspring Plc’s Half-year review January–June 2022. The complete report is attached to this release as a pdf file. It is also available on Loudspring’s website at https://loudspring.earth/   HIGHLIGHTS OF THE REVIEW PERIOD JANUARY – JUNE 2022  (

Change in the total number of shares and votes in IRRAS AB

2022-08-31 As of 31 August 2022, the total number of shares and votes in IRRAS AB (“IRRAS”) amounts to 564,240,834. The number of shares and votes in IRRAS has increased as a result of the registration of 484,759,494 ordinary shares subscribed for with subscription rights, which in accordance with previously announced information, was issued in connection with the rights issue that was resolved by the board of directors on 4 July 2022 and approved by the extraordinary general meeting held on 3 August 2022. This information is published in accordance with Chapter 4, Section 9 of the

Vattenfall and CAKE reveal hidden CO\2\ sources when producing an electric motorcycle

Leading European energy company Vattenfall and CAKE, producer of electric motorcycles, build climate awareness by defining the carbon footprint with a cube. “Fossil-free vehicles means that the entire production part needs to be decarbonized, regardless of the fuel they are running on”, says Stefan Ytterborn, founder and CEO of CAKE.Vattenfall and CAKE  today announced an innovative initiative to visualize carbon emissions from production. Within the joint project Cleanest Dirt Bike Ever , CAKE and Vattenfall are revealing the

Inzile AB (publ) Interim Report January 1 - June 30, 2022

First six months 2022 in brief · Order regarding installation of assembly factory in the Dominican Republic received from Pinero  · Order of 33 hotel & resort vehicles received from Pinero   · Order of 21 light trucks received from Tier Mobility in Finland and Norway · Record-breaking order of 900 hotel & resort vehicles received from Emos Caribbean · Måns Sjöstedt appointed CEO and Yago Mendez resigned · Enrique Banuelos, Gloria Banuelos and Juan Carlos Del Rio elected members of the Board · Ragnar Åhgren, Måns Sjöstedt, Yago Mendez and Rafael Escanez resigned from

TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

Viken, Sweden – 31[st] August 2022 – TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body’s ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed’s ILB® neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and

DanCann Pharma A/S publishes Q2-2022 report

COPENHAGEN, Denmark, 31 August 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter of 2022. The Q2-2022 report is available as an attached document to this press release and at www.dancann.com.Group key figures Q2-2022: KDKK 01/01/22 01/01/21 01/04/22 01/04/21 01/01/21 30/06/22 30/06/21 30/06/22 30/06/21 31/12/21Net sales 2,037 0 771 0 874

Zimpler strengthens senior leadership by appointing a new chairwoman and Chief Growth Officer

Stockholm, 31 August 2022 — Zimpler, a leading fintech company born in Sweden, has– with immediate effect–appointed Katarina Bonde as their new chair of the board, and Nicolas Köllerstedt as Chief Growth Officer. Bonde will replace Peo Nilsson, who will remain on as a board member.Katarina Bonde brings over 20 years of experience holding board positions for scale-up companies. She is currently on the board of several successful businesses, including a SaaS company, Mentimeter, and software company NEPA. At Zimpler, Bonde will focus on continuing the company’s sustainable growth and

Sinch announces changes to the Management Team

Stockholm, Sweden – August 31, 2022 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced that Paul Perrett, President for Business Unit SMB (Small and Medium-sized Businesses) has decided to step down to be able to spend more time with his family. Paul Perrett joined Sinch in 2021 through the acquisition of MessageMedia, a company he joined as CFO in 2018 before becoming the CEO in 2019. He will step down from the role as Business Unit President at the end of September but will maintain a part-time role until the end of December to

RugVista to boost customer experience through partnership with delivery platform Ingrid

RugVista has partnered with delivery experience platform Ingrid to give customers in key markets across Europe better access to preferred last-mile carrier options and to optimize the company’s logistics. “RugVista constantly strives to deliver an outstanding customer experience and we know that providing popular delivery and return options in each local market is critical,” says Anders Matthiesen, Chief Operating Officer at RugVista. “Teaming with Ingrid adds flexibility for our customers and allows us to continuously optimize our delivery and return experience.” Rugvista

Loyal Solutions announces half year results for 1/1-30/06 2022

Danish SaaS company Loyal Solutions delivers 31% ARR growth in first full year as a listed companyCEO Peter Kisbye comments:“The period 1 July 2021 – 30 June 2022 (“the Period”) was the first full year post our IPO (“Initial Public Offering”) on Nasdaq First North Growth Market Stockholm 3 June 2021. In our first full year as a listed company, the Company delivered close to the budgeted results, with a: · Growth in annual recurring revenue (ARR) of 31% · Top line revenue reaching 94% of budget. · EBITDA of TDKK -14,5 vs a forecasted EBITDA of -19,5 and a prospectus estimated

BioStock: Aptahem on schedule for clinical studies

Malmö-based biotech Aptahem, which is developing the drug candidate Apta-1 as a new type of emergency treatment for sepsis, released its Q2 report last week. It is clear that the company, which is approaching the first in-human studies, is so far on schedule and that more and more details are falling into place for the upcoming clinical work.Read the article at biostock.se: https://www.biostock.se/en/2022/08/aptahem-on-schedule-for-clinical-studies/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Resurs Bank signs agreement with Komplett ASA

Resurs Bank AB has entered into an interim factoring agreement with Komplett ASA.Komplett Group is one of the largest e-commerce actors on the Nordic market and market leader in the office and home electronic segment when it comes to distribution and retail. The agreement encompasses a limited number of company invoices to Komplett's subsidiary Itegra, following periods of strong growth in its distribution segment. The intention is to conclude a long-term agreement. Resurs and Komplett ASA have had good experiences working together thanks to the collaboration around Komplett's

There are no items matching the current filter
There are no more items matching the current filter
Back to top